Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of global mortality and is strongly associated with cumulative exposure to atherogenic lipoproteins across the lifespan. Author Amber E. Johnson, MD, MS, MBA, of the University of Chicago joins JAMA Senior Editor Philip Greenland, MD, to discuss the ACC/AHA guideline on management of dyslipidemia. Related Content:

• Dyslipidemia Evaluation and Management
• Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy